Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.31 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921982 | 0.90 | KDM4E (0.44) | LRRK2KDM4EALDH1A1SMN1; SMN2JAK1 | |
| SCHEMBL9918555 | 0.82 | SYK (0.36) | LRRK2ALDH1A1JAK1JAK3SYK | |
| SCHEMBL9921974 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2JAK1SYK | |
| SCHEMBL9918558 | 0.71 | HTT (0.41) | LRRK2KDM4EALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9918562 | 0.71 | SYK (0.47) | LRRK2SYK | |
| SCHEMBL12833307 | 0.71 | LRRK2 (0.43) | LRRK2SYKTTBK1TTBK2 | |
| SCHEMBL9918560 | 0.70 | JAK2 (0.34) | LRRK2JAK1JAK3SYK | |
| SCHEMBL9918545 | 0.70 | CSF1R (0.46) | LRRK2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9918556 | 0.69 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2JAK1JAK3NPC1 | |
| SCHEMBL12832928 | 0.68 | LRRK2 (0.45) | LRRK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LRRK2 1567/4885KDM4E 477/4885ALDH1A1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.